How much revenue did Alterity Therapeutics generate this year?
Alterity Therapeutics has achieved a revenue of 16,440 AUD this year.
Alterity Therapeutics Revenue 2024
Alterity Therapeutics Revenue
16,440 AUD
Ticker
ATH.AX
ISIN
AU0000043945
WKN
A2PHDZ
In 2024, Alterity Therapeutics's sales reached 16,440 AUD, a 557.6% difference from the 2,500 AUD sales recorded in the previous year.
The Alterity Therapeutics Revenue history
| YEAR | REVENUE (undefined AUD) | GROSS MARGIN (%) |
|---|---|---|
| 2023 | 0.02 | 22110,71 |
| 2022 | 0 | 190200,00 |
| 2021 | 0.02 | 19245,65 |
| 2020 | 0.02 | -2061,92 |
| 2019 | 0.11 | 3349,00 |
| 2018 | 0.2 | 1806,93 |
| 2017 | 0.13 | 2745,47 |
| 2016 | 0.14 | 2548,02 |
| 2015 | 0.18 | 2055,53 |
| 2014 | 0.36 | 1009,72 |
| 2013 | 0.15 | 2423,33 |
| 2012 | 0.19 | 1913,16 |
| 2011 | 0.16 | 2271,87 |
| 2010 | 0.22 | 1652,27 |
| 2009 | 0.43 | 845,35 |
| 2008 | 0.49 | 741,84 |
| 2007 | 0.51 | 712,75 |
| 2006 | 1.05 | 346,19 |
| 2005 | 2.65 | 137,17 |
| 2004 | 2.32 | 156,68 |
Alterity Therapeutics Revenue, EBIT, Net Income AU0000043945 · A2PHDZ
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Alterity Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Alterity Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Alterity Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Alterity Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Alterity Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Alterity Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Alterity Therapeutics’s growth potential.
Alterity Therapeutics Revenue, Profit, and EBIT History
| Date | Alterity Therapeutics Revenue | Alterity Therapeutics EBIT | Alterity Therapeutics Net Income |
|---|---|---|---|
| 2023 | 16,440 undefined | -14.62 M undefined | -13.81 M undefined |
| 2022 | 2,500 undefined | -15.95 M undefined | -12.85 M undefined |
| 2021 | 20,680 undefined | -15.37 M undefined | -15.31 M undefined |
| 2020 | 17,120 undefined | -13.91 M undefined | -13.46 M undefined |
| 2019 | 108,540 undefined | -12.69 M undefined | -12.34 M undefined |
| 2018 | 201,170 undefined | -7.99 M undefined | -8.27 M undefined |
| 2017 | 132,400 undefined | -6.88 M undefined | -7.54 M undefined |
| 2016 | 142,660 undefined | -8.59 M undefined | -7.73 M undefined |
| 2015 | 176,840 undefined | -17.01 M undefined | -5.89 M undefined |
| 2014 | 360,000 undefined | -20.37 M undefined | -13.33 M undefined |
| 2013 | 150,000 undefined | -12.27 M undefined | -7.79 M undefined |
| 2012 | 190,000 undefined | -5.31 M undefined | -5.24 M undefined |
| 2011 | 160,000 undefined | -6.27 M undefined | -6.43 M undefined |
| 2010 | 220,000 undefined | -4.9 M undefined | -4.91 M undefined |
| 2009 | 430,000 undefined | -8.29 M undefined | -7.53 M undefined |
| 2008 | 490,000 undefined | -12.71 M undefined | -13.56 M undefined |
| 2007 | 510,000 undefined | -10.99 M undefined | -11.14 M undefined |
| 2006 | 1.05 M undefined | -11.94 M undefined | -11.72 M undefined |
| 2005 | 2.65 M undefined | -12.79 M undefined | -25.01 M undefined |
| 2004 | 2.32 M undefined | -9.39 M undefined | -9.89 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 2.32 M AUD | -9.39 M AUD | -9.89 M AUD |
| 2005 | 2.65 M AUD | -12.79 M AUD | -25.01 M AUD |
| 2006 | 1.05 M AUD | -11.94 M AUD | -11.72 M AUD |
| 2007 | 510,000 AUD | -10.99 M AUD | -11.14 M AUD |
| 2008 | 490,000 AUD | -12.71 M AUD | -13.56 M AUD |
| 2009 | 430,000 AUD | -8.29 M AUD | -7.53 M AUD |
| 2010 | 220,000 AUD | -4.9 M AUD | -4.91 M AUD |
| 2011 | 160,000 AUD | -6.27 M AUD | -6.43 M AUD |
| 2012 | 190,000 AUD | -5.31 M AUD | -5.24 M AUD |
| 2013 | 150,000 AUD | -12.27 M AUD | -7.79 M AUD |
| 2014 | 360,000 AUD | -20.37 M AUD | -13.33 M AUD |
| 2015 | 176,840 AUD | -17.01 M AUD | -5.89 M AUD |
| 2016 | 142,660 AUD | -8.59 M AUD | -7.73 M AUD |
| 2017 | 132,400 AUD | -6.88 M AUD | -7.54 M AUD |
| 2018 | 201,170 AUD | -7.99 M AUD | -8.27 M AUD |
| 2019 | 108,540 AUD | -12.69 M AUD | -12.34 M AUD |
| 2020 | 17,120 AUD | -13.91 M AUD | -13.46 M AUD |
| 2021 | 20,680 AUD | -15.37 M AUD | -15.31 M AUD |
| 2022 | 2,500 AUD | -15.95 M AUD | -12.85 M AUD |
| 2023 | 16,440 AUD | -14.62 M AUD | -13.81 M AUD |
Alterity Therapeutics stock margins AU0000043945 · A2PHDZ
The Alterity Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alterity Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alterity Therapeutics.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Alterity Therapeutics's sales revenue. A higher gross margin percentage indicates that the Alterity Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Alterity Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Alterity Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Alterity Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Alterity Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Alterity Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Alterity Therapeutics Margin History
| Alterity Therapeutics Gross margin | Alterity Therapeutics Profit margin | Alterity Therapeutics EBIT margin | Alterity Therapeutics Profit margin |
|---|---|---|---|
| 2023 | 22,110.71 % | -88,940.45 % | -83,981.27 % |
| 2022 | 190,200.01 % | -638,144.43 % | -513,882.4 % |
| 2021 | 19,245.65 % | -74,328.35 % | -74,029.74 % |
| 2020 | -2,061.92 % | -81,265.07 % | -78,602.81 % |
| 2019 | 22,110.71 % | -11,688.68 % | -11,367.08 % |
| 2018 | 22,110.71 % | -3,974.19 % | -4,108.83 % |
| 2017 | 22,110.71 % | -5,197.78 % | -5,696.43 % |
| 2016 | 22,110.71 % | -6,019.07 % | -5,418.16 % |
| 2015 | 22,110.71 % | -9,619.02 % | -3,327.91 % |
| 2014 | 22,110.71 % | -5,658.33 % | -3,702.78 % |
| 2013 | 22,110.71 % | -8,180 % | -5,193.33 % |
| 2012 | 22,110.71 % | -2,794.74 % | -2,757.89 % |
| 2011 | 22,110.71 % | -3,918.75 % | -4,018.75 % |
| 2010 | 22,110.71 % | -2,227.27 % | -2,231.82 % |
| 2009 | 22,110.71 % | -1,927.91 % | -1,751.16 % |
| 2008 | 22,110.71 % | -2,593.88 % | -2,767.35 % |
| 2007 | 22,110.71 % | -2,154.9 % | -2,184.31 % |
| 2006 | 22,110.71 % | -1,137.14 % | -1,116.19 % |
| 2005 | 22,110.71 % | -482.64 % | -943.77 % |
| 2004 | 22,110.71 % | -404.74 % | -426.29 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 22,110.71 % | -404.74 % | -426.29 % |
| 2005 | 22,110.71 % | -482.64 % | -943.77 % |
| 2006 | 22,110.71 % | -1,137.14 % | -1,116.19 % |
| 2007 | 22,110.71 % | -2,154.9 % | -2,184.31 % |
| 2008 | 22,110.71 % | -2,593.88 % | -2,767.35 % |
| 2009 | 22,110.71 % | -1,927.91 % | -1,751.16 % |
| 2010 | 22,110.71 % | -2,227.27 % | -2,231.82 % |
| 2011 | 22,110.71 % | -3,918.75 % | -4,018.75 % |
| 2012 | 22,110.71 % | -2,794.74 % | -2,757.89 % |
| 2013 | 22,110.71 % | -8,180 % | -5,193.33 % |
| 2014 | 22,110.71 % | -5,658.33 % | -3,702.78 % |
| 2015 | 22,110.71 % | -9,619.02 % | -3,327.91 % |
| 2016 | 22,110.71 % | -6,019.07 % | -5,418.16 % |
| 2017 | 22,110.71 % | -5,197.78 % | -5,696.43 % |
| 2018 | 22,110.71 % | -3,974.19 % | -4,108.83 % |
| 2019 | 22,110.71 % | -11,688.68 % | -11,367.08 % |
| 2020 | -2,061.92 % | -81,265.07 % | -78,602.81 % |
| 2021 | 19,245.65 % | -74,328.35 % | -74,029.74 % |
| 2022 | 190,200.01 % | -638,144.43 % | -513,882.4 % |
| 2023 | 22,110.71 % | -88,940.45 % | -83,981.27 % |
Alterity Therapeutics Aktienanalyse
What does Alterity Therapeutics do?
Alterity Therapeutics Ltd is an Australian company specializing in the discovery and development of therapeutics for neurodegenerative diseases. The company's history dates back to 1997 when it was established under the name Prana Biotechnology Limited. Alterity Therapeutics' business model is based on the research of protein aggregates responsible for neurodegenerative diseases. The company primarily focuses on developing drugs targeting the breakdown of these protein aggregates to minimize the effects of diseases such as Parkinson's, Alzheimer's, and Huntington's. The company has several divisions specializing in various aspects of product development, including preclinical research, clinical development, and commercial marketing. Alterity Therapeutics has several products in various stages of development. One of its leading products is PBT434, a drug that aims to prevent protein aggregates in the brain and target the treatment of Parkinson's disease. The drug has already been tested in clinical trials and has shown promising results. In addition to PBT434, the company also has other promising drugs in development, including PBT519, targeting the treatment of Alzheimer's disease, and PBT2, targeting the treatment of Huntington's disease. Alterity Therapeutics aims to minimize the impact of neurodegenerative diseases and improve the quality of life for millions of patients worldwide. The company collaborates with leading medical and academic institutions to develop innovative therapeutics that meet the needs of patients and clinicians. Overall, Alterity Therapeutics offers a promising pipeline of drugs that could play a significant role in the treatment of neurodegenerative diseases. The company has become a major player in the industry and has the potential to make a significant impact in the fight against these serious illnesses. Alterity Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Alterity Therapeutics's Sales Figures
The sales figures of Alterity Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Alterity Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Alterity Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Alterity Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Alterity Therapeutics Stock
How much was the turnover of the company Alterity Therapeutics compared to the previous year?
The revenue of Alterity Therapeutics has increased by 557.6% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Alterity Therapeutics?
The revenue of Alterity Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Alterity Therapeutics measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Alterity Therapeutics so important for investors?
The revenue of Alterity Therapeutics is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Alterity Therapeutics pay?
Over the past 12 months, Alterity Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alterity Therapeutics is expected to pay a dividend of 0 AUD.
What is the dividend yield of Alterity Therapeutics?
The current dividend yield of Alterity Therapeutics is .
When does Alterity Therapeutics pay dividends?
Alterity Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Alterity Therapeutics?
Alterity Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Alterity Therapeutics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Alterity Therapeutics located?
Alterity Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Alterity Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Alterity Therapeutics from 6/27/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.
When did Alterity Therapeutics pay the last dividend?
The last dividend was paid out on 6/27/2024.
What was the dividend of Alterity Therapeutics in the year 2023?
In the year 2023, Alterity Therapeutics distributed 0 AUD as dividends.
In which currency does Alterity Therapeutics pay out the dividend?
The dividends of Alterity Therapeutics are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Alterity Therapeutics
Our stock analysis for Alterity Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alterity Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Alterity Therapeutics Revenue
- Alterity Therapeutics Net Income
- Alterity Therapeutics P/E
- Alterity Therapeutics P/S
- Alterity Therapeutics EBIT
- Alterity Therapeutics Dividend
- Alterity Therapeutics Stocks
- Alterity Therapeutics Market capitalization
- Alterity Therapeutics Debt
- Alterity Therapeutics Liabilities
- Alterity Therapeutics Equity
- Alterity Therapeutics AAQS
- Alterity Therapeutics Employees
- Alterity Therapeutics ROE
- Alterity Therapeutics ROA
- Alterity Therapeutics ROCE
